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Abstract In order to stabilize the C-terminal dodecapeptide of 
neuropeptide Y (NPY) we replaced Leu 2s and Thr 32 by Lys and 
Glu, respectively, and subsequently linked these residues by 
lactamization. This peptide analog of NPY shows a more than 
100-fold increase in affinity compared to the C-terminal linear 
dodecapeptide in receptor binding studies performed at human 
neuroblastoma cells SMS-KAN, which exclusively express the 
Y2 receptor subtype.2+ Signal transduction was investigated" by 
measuring Ca current inhibition in human SH-SY5Y cells and 
cyclic [Lys2S-Glu3Z] NPY Ac-25-36 and NPY were shown to be 
equipotent in this assay. Thus, this molecule is the smallest Y2 
receptor selective full agonist of NPY. Using 2D-NMR 
experiments and molecular modelling techniques, the structures 
of the linear and cyclic peptides have been investigated and 
significant differences have been found, which may explain the 
improvement in biological activity. Thus, a model of the bioactive 
conformation of NPY at the human Yz receptor is suggested. 
Key words: Neuropeptide Y; Peptide synthesis; Receptor 
binding; Bioactive conformation; NMR 
1. Introduction 
Neuropeptide Y (NPY) is a 36-peptide amide which ex- 
hibits a high homology with the pancreatic polypeptide (PP) 
and peptide YY (PYY) in both sequence and 3D structure 
[1,2]. It was isolated from pig brain and sequenced in 1982 
[3]. NPY is one of the most abundant neurohormones in the 
mammalian peripheral and central nervous systems. Receptor 
competition binding studies using analogs or segments of 
NPY, PYY and PP revealed that at least four receptor sub- 
types (YI, Y2, Y3, Y4) exist [4,5]. The Y1, Y2, and Y4 recep- 
tors have been cloned recently and it could be shown that they 
all belong to the G-protein coupled receptor family. Whereas 
NPY shows high affinity to Y1 and Y2 receptors, PP is sup- 
posed to be the endogenous ligand of the Y4 receptor [5]. 
Y2 receptors are predominantly localized on the presynaptic 
membrane of postganglionic, sympathetic neurons of the per- 
ipheral nervous system. In addition, Y2 receptors have been 
identified in the proximal tubuli of kidneys, in the parasym- 
pathetic neurons and in red cells of rats using autoradiogra- 
phy. Centrally, the Y2 receptor is more dominant han the Y1 
subtype. In the hippocampus of rats only Y2 receptors are 
found as well as at the nerve ends of stimulating neurons 
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which are synaptically bound to the hippocampus CA1 neu- 
rons. Y2 receptors mediate the inhibitory effects of NPY on, 
amongst others, ion excretion in the rat small intestine, adre- 
naline release in the mesenteric arteries and bronchial contrac- 
tion in guinea pig. One of the most important activities of the 
neurohormone - as shown with NPY knock-out mice is the 
control of neural excitability, because it suppresses glutamate 
release from neurons in the hippocampus [6]. Furthermore, 
elevation of memory retention of rats and modulation of 
other neurotransmitters have been reported (for recent re- 
views, see [4,7,8]). 
Cell lines exclusively expressing the Y2 receptor were iden- 
tified, and signal transduction was characterized as inhibition 
of cAMP accumulation (LN319 astrocytoma cells) [9] or in- 
hibition of N-type Ca 2+ channel current amplitudes (SH- 
SY5Y neuroblastoma cells) [10,11]. In each case the effect 
was pertussis toxin sensitive, which suggests the involvement 
of inhibitory G-protein. 
Structure activity studies of neuropeptide Y and analogs at 
the Y2 receptor evealed that the entire molecule is not re- 
quired for full activity. So far, the 24-mer peptide NPY(13- 
36) is most frequently used for the testing of Y2 receptor 
mediated actions [4]. We and others have shown recently 
that smaller centrally or N-terminally truncated analogs 
such as [Ahx 5-24] NPY are full Y2 receptor agonists [9] or 
show at least good binding properties [12-15]. In addition, 
the L-Ala scan of NPY 1-36 suggests that only the C-terminal 
amino acids are involved in receptor binding and we specu- 
lated that the N-terminal residues only serve for the stabiliza- 
tion of the molecule [16]. We have now succeeded in develop- 
ing a small molecule, which only consists of the C-terminal 12 
amino acids, and which has been stabilized by an intramole- 
cular lactam bridge. This synthetic yclopeptide shows high, 
selective Y2 receptor affinity and activity, which is comparable 
to the activity of the native agonist. In addition, we solved the 
3D solution structure of this molecule using 2D NMR tech- 
niques and compared it with the linear, inactive peptide. We 
also propose a model for the bioactive conformation of NPY 
at the Y2 receptor. 
2. Materials and methods 
2.1. Materials 
Fmoc-protected amino acids and 2-(1H-benzotriazol-l-yl)-l,l,3,3- 
tetramethyluronium-tetrafluoroborate (TBTU) were obtained from 
NovaBiochem (L~iufelfingen, Switzerland), aminomethylated polystyr- 
ene from Rapp Polymere (Tiibingen, Germany) diisopropylcarbodi- 
imide and thiocresol from Aldrich, 1-hydroxybenzotriazole (HOBt), 
diisopropylethylamine, trifluoroacetic acid, thioanisole and piperidine 
from Fluka and dimethylformamide (p,a. grade), diethyl ether, aceto- 
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nitrile and tert.-butyl alcohol from Merck. HEPES, Tris, bovine ser- 
um albumin, bacitracin, gentamycin and pentamethylsutfonylfluoride 
were purchased from Sigma, polyethylene imine and Fmoc-amino- 
methyldimethoxyphenoxy valeric acid from Serva, sodium pyruvate, 
minimum essential medium with Earle's salts and Ham's F12/50% 
Dulbecco's modified Eagle medium from Gibco, fetal calf serum, glu- 
tamine and non-essential mino acids from Boehringer Mannheim. 
EDTA and all salts for preparing the buffers were either from Fluka 
or from Merck. [125I]Bolton Hunter NPY was ordered from Anawa 
(Ztirich, Switzerland) and its specific activity was 81 TBq/mmol. 
[3H]Propionyl NPY (specific activity 3.2 TBq/mmol) was purchased 
from Amersham. 
2.2. Peptide synthesis, purification and analysis" 
The linear peptide was synthesized by automated, multiple solid 
phase peptide synthesis using a robot system (Syro, MultiSynTech, 
Bochum) and applying Fmoc/tBu strategy as described previously [17]. 
The N-terminus of the peptide was acetylated while it was still fully 
protected and bound to the resin. The linear peptide amide was 
cleaved with trifluoroacetic a id/thioanisole/thiocresol within 3 h, col- 
lected by centrifugation and lyophilized from water. For cyclization 
the unprotected but N-terminal acetylated dodecapeptide amide (1 eq) 
was dissolved in N,N-dimethylformamide (2 mM), l-hydroxy-benzo- 
triazole (3 eq), TBTU (3 eq) and diisopropylethylamine (1%v/v) were 
added. After shaking for 2 h the solvent was removed at reduced 
pressure. The residue was dissolved in trifluoroacetic acid and pre- 
cipitated from cold diethyl ether. The product was collected by cen- 
trifugation and resuspended twice in diethyl ether. Finally it was lyo- 
philized from water. The cyclic product was purified by preparative 
HPLC on a Nucleosil C-18 column and eluted with 21% acetonitrile. 
The peptide was investigated by analytical HPLC (Nucleosil C-18 
column, 5, 1200×3 mm, Merck-Hitachi, Darmstadt), purity was 
> 98%. Correct mass was identified by ion-spray mass spectrometry 
(API III, Sciex, Toronto): Mr×p: 1698.6 + 1.0 amu (Mth : 1698.9 ainu). 
Amino acid analysis was as expected Leu 1.00 (1), Arg 3.20 (3), His 
1.11 (1), Tyr 1.89 (2), lle 0.95 (1), Asx 1.10 (1), Lys 0.89 (1), Glx 2.06 
(2). 
2.3. NMR experiments and molecular modelling 
The 3D structure of the cyclic [Lys2S-Glu 32] NPY Ac-25 36 and the 
linear peptide [Lys2S,Glu 32] NPY Ac-25-36 was obtained from 2D 
[1H]NMR experiments using 80 ms [1H,1H]TOCSY, [1H,IH]DQF- 
COSY and 300 ms [3H,1H]ROESY experiments in standard procedure 
[18]. Whereas both peptides are unstructured in aqueous olution, 
upon addition of TFE-d3, which is known to stabilize structures in- 
volving hydrogen bonds [19], medium- and long-range NOEs become 
visible. Therefore, spectra were recorded on 3 mM solutions of the 
peptides in 30% TFE-d3/H20 at 600 MHz with solvent suppression 
being achieved through low-power preirradiation. Spectra had to be 
run at 35°C since the cyclic peptide displayed broad lines for the 
residues involved in the ring presumably due to conformational ex- 
change at lower temperatures. In addition to the distance constraints 
derived from the ROESY experiment, 3J(H~HCC~) scalar coupling con- 
stants were extracted from the ROESY spectrum using the INFIT 
method [20]. Distance and dihedral angle constraints were used as 
input for distance geometry calculations computed with the DIANA 
package [21] The conformational space spanned by the 10 lowest 
energy DIANA structures i displayed in Fig. 3. 
The 10 DIANA structures were then energy minimized using the 
forcefield of AMBER4.1 [22] with the standard parameter set parm94. 
The peptide was centered in a 7.5 ,~ thick shell of TIP3P water mol- 
ecules [23] without positional constraining of the solvent molecules, 
discarding any water atom closer than 1.75 A to any solute atom and 
assuming a dielectric constant of 1. During the minimization the lac- 
tam bond was held fixed through additional distance constraints. A 
residue-based cutoff of 10 A, a secondary cutoff of 15 A and the all- 
atom mode were applied. The structure of the solvated peptide was 
energy minimized by 1000 steps of steepest descent followed by a 
conjugate gradient minimization procedure until the rms gradient of 
the potential energy was less than 0.02 kcal/mol.,~. Finally, the quality 
of the minimized structures was checked by means of the program 
PROCHECK [24]. 
2.4. Membrane preparation and receptor binding 
SMS-KAN cells and SK-N-MC cells were grown in 50% nutrient 
mixture Ham's FI 2/50% Dulbecco's modified Eagle medium with 15% 
fetal calf serum, 2 mM glutamine, non-essential mino acids, 1% 
gentamycin at37°C and 5% CO2 until they were confluent. Membrane 
suspensions were prepared as described previously [16]. 
2.5. Receptor binding 
For binding studies membrane suspensions (100 [al) obtained from 
SMS-KAN (YD or SK-N-MC (Y2) cells were incubated with 30 pM 
[125I]Bolton Hunter NPY (12~I-BH-NPY) or 1.2 nM [aH]propionyl- 
NPY (3H-NPY) and different concentrations of the peptide in a total 
volume of 250 ~tl for 2 h at room temperature asdescribed recently 
[16]. Non-specific binding was defined in the presence of 1 IaM NPY. 
Half maximal inhibition of the specific binding of the 12~I-BH-NPY 
and the 3H-NPY of two to three separate xperiments is given as the 
Ki value (mean + S.E.M.). Eleven concentrations of the competitors 
were chosen to bracket he Ki value and to cover six orders of mag- 
nitude. All competitor curves were fitted with a monophasic binding 
profile suggesting a single binding site. 
2.6. Biological assays 
Whole-cell Ca 2+ channel currents were recorded in SH-SY5Y cells 
using the amphotericin B perforated-patch technique as previously 
described [10], using 10 mM Ba 2+ as charge carrier. Cells were per- 
fused with a solution of composition: NaC1 110 mM, CsCl 5 mM, 
MgC12 0.6 raM, BaCI2 10 mM, HEPES 5 mM, glucose 10 mM, 
tetraethylammonium chloride (TEA) 20 mM (pH 7.4, 21-24°C). Patch 
electrodes (resistances 2 8 M) were filled with a solution of CsC1 120 
mM, TEA 20 mM, EGTA 10 mM, MgCI2 2 raM, HEPES 10 mM. 
Amphotericin B was also present at a concentration of 240 ~tg/ml 
(from a stock solution of 60 mg/ml made in dimethylsulfoxide) and 
experiments were performed at low light intensity. Cells were voltage 
clamped at -80 mV and Ca 2+ channel currents were evoked by 200 
ms step depolarizations, applied at a frequency of 0.2 Hz. Current 
amplitudes were measured at their peak following leak subtraction as 
previously described [10], and residual capacitance urrents have been 
omitted for illustrations. 
3. Results and discussion 
The cyclic analog of the C-terminal segment [Lys2S-Glu 32] 
NPY Ac-25 36 was synthesized and a high affinity to human 
Y2 receptors on SMS-KAN cells was found (Table 1). This is 
20-fold increased compared to the linear peptide NPY Ac-25- 
36 and more than 100-fold increased compared to 
[Lys2S,Glu 32] NPY Ac-25-36, the linear peptide with the 
same replacements a the cyclic one. In contrast, Y1 receptor 
binding was reduced by more than 4 orders of magnitude 
compared to NPY and Y1 selective [Pro 34] NPY. The cyclic 
peptide was obtained by lactamization of Lys and Glu after 
replacement of Leu z8 and Thr 32 of the native sequence (Fig. 
1). These residues had been identified by means of the c-ala- 
nine scan not to contribute to the binding of the peptide [16]. 
Furthermore, activity studies have been performed: as pre- 
viously described [10], bath applications of NPY cause con- 
centration-dependent, reversible inhibitions of Ca 2+ channel 
current amplitudes in SH-SY5Y human neuroblastoma cells 
Table 1 
Affinity of NPY and analogs to human neuroblastoma cells selec- 
tively expressing Y1 or Y2 receptors 
SMS-KAN (Y2) SK-MC (Y1) 
(K~ [nM]) (Ki [nM]) 
NPY 0.04 + 0.01 0.2 + 0.05 
[Pro 34] NPY 15.3 + 0.9 0.3 + 0.04 
NPY Ac-25-36 21 +0.9 > 10000 
[Lys2S-Glu32] NPY Ac-25 36 > 1000 > 10000 
cyclo[Lys28-Glu 32] NPY Ac-25-36 0.9 + 0.3 > 10000 






Fig. 1. Scheme of the acetylated C-terminal segment of neuropeptide 
Y and [Lys28-Glu :~2] NPY Ac-25 36. Exchanged residues and lactam 
bridge are marked in gray. 
as shown in Fig. 2A. This inhibitory effect is mediated by Y2 
receptors coupled to pertussis toxin sensitive G-proteins. The 
concentration-response relationship for inhibition of Ca 2+ 
channel current amplitude NPY is given by filled circles 
(Fig. 2C). Like NPY, [Lys2S-Glu32] NPY Ac-25-36 also rever- 
sibly inhibits the currents in SH-SY5Y cells (Fig. 2B), and the 
potency of [Lys28-Glu 32] NPY Ac-25-36 was similar to that of 
NPY (Fig. 2C, open circles). These results indicate that 
[Lys28-Glu 32] NPY Ac-25 36 is a full agonist at Y2 receptors 
in the human neuroblastoma cell line SH-SY5Y and therefore 
the lowest molecular weight analog of NPY known to date. 
In the initial studies characterizing NPY receptor subtypes 
[4], the Y2 receptor was distinguished from the Y1 receptor by 
the fact that the former can recognize C-terminal segments of 
the hormone. Further investigations showed that activity is 
maintained in the C-terminal moiety, such as NPY(16~36) 
[25]. These results led us to speculate that a modified segment 
of NPY Ac-25 36 could be sufficient for Y2 receptor ecogni- 
tion. The decrease of binding capacity of [Lys2S-Glu 32] NPY 
Ac-25-36 compared to NPY could be due to the lack of 
stability under the conditions of the binding assay as a differ- 
ent behavior of C-terminal analogs has been reported before 
[26]. 
The linear peptide [Lys28,Glu a2] NPY Ac-25-36 and the 
cyclopeptide [Lys%-Glu 32] NPY Ac-25-36 have been investi- 
gated by 2D-NMR experiments in order to characterize their 
structure. NMR data reveal sequential HN-H N NOE contacts 
at the C-terminus for both the linear and the cyclized peptide. 
These close contacts are indicative of a C-terminal helical 
winding of the backbone, which for both peptides tarts at 
Asn 29 and extends to residue Tyr 36 for the linear peptide and 
to Gln 34 for the cyclic peptide (Fig. 3), where it is followed by 
a turn. However, NOEs between residues from the C- and N- 
terminus uch as between the sidechains of residues His 26 and 
Tyr 36 have only been detected for the cyclic analog. Using the 
distances obtained from the ROESY experiment a 3D model 
has been built up. The results suggest hat the biologically 
active conformation of the C-terminal part of NPY is very 
similar to the tertiary structure of [Lys2S-Glu a2] NPY Ac-25- 
36. Further evidence for the C-terminal helix derives from CD 
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Fig. 2. Example currents evoked in a SH-SY5Y cell by step depolarizations from -80 to 0 mV before (c) and during bath application of 100 
nM NPY (A, o) or [Lys2S-Glu ~2] NPY Ac-25-36 (B, ©). Scale bars apply to both A and B. (C) Log concentration-response curves indicating 
mean percentage inhibition of peak inward current amplitudes caused by NPY (e) and [Lys2S-Glu :~2] NPY Ac-25-36 (©). Each point is the 
mean with vertical standard error bars taken from 4-14 cells in each case. 
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Fig. 3. Superposition of backbone atoms of residues 4 8 of the energy minimized DIANA structures. The less well defined carbon atoms of the 
lactam bridge are indicated by thin lines, whereas for the rest of the backbone atoms the envelope of the structure bundle is displayed. The 
drawing was prepared using the program MOLMOL [32]. 
measurements (data not shown). In order to estimate the ex- 
tent to which the peptides are structurally ordered, we com- 
pared their vicinal H~-H ca scalar coupling constants. Vicinal 
HN-H ca scalar coupling constants mostly close to 6.5 Hz for 
the case of the linear peptide indicate a low population of the 
helical structure in spite of the detected sequential amide ROE 
contacts. In contrast, coupling constants of [Lys2S-Glu :~2] 
NPY Ac-25-36 close to 5.5 Hz for the helical segment or 
8.9 Hz for the residues involved in the turn indicate that the 
structure displayed in Fig. 3 is much higher populated, not 
only in the rigid cycle, but also at both termini. In good 
agreement with this structure, Y2 receptor affinity could be 
correlated with helicity [27]. 
A comparison of the 3D model of NPY (Fig. 4A) to that of 
[Lys2S-Glu a2] NPY Ac-25 36 (Fig. 4B) reveals that both pep- 
tides display a hairpin-like structure, in which the N-terminus 
covers one side of the C-terminal helix. We propose that this 
feature is necessary for biological function. Evidence stems 
from the fact that residues of the N-terminal part of NPY 
can be substituted without loss of biological activity. Further- 
more, the size, the orientation and the position of the lactam 
ring play an important role (Rist et al., unpublished data) 
suggesting that the orientation of the C-terminal helix with 
respect to the N-terminus is of major importance. This is 
supported by the observation that the major difference be- 
tween the inactive linear and the active cyclic peptide was 
the orientation of the C-terminal amino acids Arg3~-Tyr :~% 
NH2: whereas for the linear peptide this dipeptide is part of 
the helix, in the case of the cyclic derivative the last two 
residues are involved in a bend which orients the C-terminus 
towards the N-terminus. 
Our 3D-structure of [Lys2S-Glu 32] NPY Ac-25--36 is in good 
agreement with previous structure activity studies: Pro a4 
would disturb this conformation, thus reducing Y2 affinity. 
So the Y~ receptor selectivity of all Pro 3'1 analogs can be 
explained [28]. Analogs of Ac-25-36 with replacement of 
Asn 29, Leu a° or Ile 31 by helix reducing amino acids (Gly, D- 
aa) have been found inactive [29] and large hydrophobic res- 
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Fig. 4. Ribbon representation f NPY (Y2) (left) [16] and the NMR 
mean structure of [Lys2S-Glu32] NPY (right). The N-terminal Arg 1 
of [Lys2S-Glu32] NPY corresponds to Arg 25 in the sequence of 
NPY. The lactam bridge is shown as a thin line. The drawing was 
prepared by means of program InsightlI (Biosym Inc., San Diego, 
CA). 
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found for C-terminal analogs with replacement of Glu 34 by 
Leu and Thr ~2 by Tyr [31]. 
Our predictions have been confirmed in the present study 
since we have succeeded in developing a cyclic dodecapeptide 
exhibiting high receptor affinity and agonistic properties as 
strong as NPY itself. The 3D structure of the cyclic peptide 
was found to be stable and could be well characterized. 
Acknowledgements." We gratefully acknowledge the support of the 
Swiss National Fund for Grant No. 31-40860.94. 
References 
[1] Glover, I., Haneef, I., Pitts, J., Wood, S., Moss, D., Tickle, I. and 
Blundell, T. (1983) Biopolymers 22, 293 304. 
[2] Allen, J., Novotny, J., Martin, J. and Heinrich, G. (1987) Proc. 
Natl. Acad. Sci. USA 84, 2532-2536. 
[3] Tatemoto, K., Carlquist, M. and Mutt, V. (1982) Nature 296, 
659-660. 
[4] Grundemar, L., Sheikh, S.P. and Wahlestedt, C. (1993) in: The 
Biology of Neuropeptide Y and Related Peptides (Colmers, W.F. 
and Wahlestedt, C., eds.), pp. 197 239, Humana Press, Totowa, 
NJ. 
[5] Bard, J.A., Walker M.W., Branchek, T.A. and Weinshank, R.L. 
(1995) J. Biol. Chem. 270, 26762-26765. 
[6] Erickson, J.C., Clegg, K.E. and Palmiter, R.D. (1996) Nature 
381,415-418. 
[7] Colmers, W.F. and Bleakman, D. (1994) Trends Neurosci. 17, 
373 379. 
[8] Beck-Sickinger, A.G. and Jung, G. (1995) Biopolymers (Peptide 
Sci.) 37, 123 142. 
[9] Beck-Sickinger, A.G., Grouzmann, E., Hoffmann, E., Gaida, W., 
Van Meier, E.G., Waeber, B. and Jung, G. (1992) Eur. J. Bio- 
chem. 206, 957- 964. 
[10] McDonald, R.L., Vaughan, P.F.T., Beck-Sickinger, A.G. and 
Peers, C. (1995) Neuropharmacology 34, 1507 1514. 
[11] McDonald, R.L., Beck-Sickinger, A.G., Rist, B., Vaughan, 
P.F.T. and Peers, C. (1995) Neurosci. Lett. 190, 179-182. 
[12] Beck, A., Jung, G., Gaida, W., K6ppen, H., Lang, R. and 
Schnorrenberg, G. (1989) FEBS Lett. 244, 119-122. 
[13] Reymond, M.T., Delmas, L., Koerber, S.C., Brown, M. R. and 
Rivier, J.E. (1992) J. Med. Chem. 35, 3653-3659. 
[14] Krstenansky, J.L., Owen, T.J., Buck, S.H., Hagaman, K. A., 
(1989) Proc. Natl. Acad. Sci. USA 86, 4377-4381. 
[15] Leban, J.J., Heyer, D., Landavazo, A., Matthews, J., Aulabaugh, 
A. and Daniels, A.J. (1995) J. Med. Chem. 38, 1150 1157. 
[16] Beck-Sickinger, A.G., Wieland, H.A., Wittneben, H., Willim, 
K.-D., Rudolf, K. and Jung, G. (1994) Eur. J. Biochem. 225, 
947-958. 
[17] Rist, B., Wieland, H.A., Willim, K.-D. and Beck-Sickinger, A.G. 
(1995) J. Peptide Sci. 1, 341 348. 
[18] Wfithrich, K. (1986) NMR of Proteins and Nucleic Acids, Wiley, 
New York. 
[19] Cammers-Goodwin, A. Allen, T.J., Oslick, S.L., McClure, K.F., 
Lee, J.H. and Kemp, D.S. (1996) J. Am. Chem. Soc. 118, 3082 
3090. 
[20] Szyperski, T., Giintert, P., Otting, G. and Wtithrich, K. (1992) 
J. Magnet. Reson. 99, 552 560. 
[21] Giintert, P., Braun, W. and Wiithrich, K. (1991) J. Mol. Biol. 
217, 517-30. 
[22] Perlman, D.A., Case, D.A., Caldwell, J.W., Ross, W.S., 
Cheatham II1, T.E., Ferguson, D.M., Seibel, G.L., Singh, U.C., 
Weiner, P.K. and Kollman, P. (1995) AMBER 4.1, University of 
California, San Francisco, CA. 
[23] Jorgensen, W.L, Chandrasekhar, J. Madura, J.D., Impey, R.W. 
and Klein, M. (1983) J. Chem. Phys. 79, 926935. 
[24] Laskowski, R.A., MacArthur, M.W., Moos, D.S. and Thornton, 
J.M. (1993) J. Appl. Crystallogr. 26, 283-291. 
[25] Colmers, W.F., Klapstein, G.J., Fournier, A., St-Pierre, S. and 
Trehere, K.A. (1991) J. Pharmacol. 102, 41-44. 
[26] Willim, K.-D., Wieland, H.A. and Doods, H.N. (1993) Naunyn 
Schmiedeberg's Arch. Pharmacol. 347, 611. 
[27] Jung, G., Beck-Sickinger, A.G., Dfirr, H., Gaida, W. and 
Schnorrenberg, G. (1991) Biopolymers 31, 613-619. 
[28] Fuhlendorff, J., Langeland-Johansen, N. Melberg, S.G., Thoger- 
sen, H., and Schwartz, T.W. (1990) J. Biol. Chem. 265, 11706- 
11712. 
[29] Schnorrenberg, G. (1992) Chimica Oggi 10, 33 36. 
[30] Beck-Sickinger, A.G., Hoffmann, E., Gaida, W., Grouzmann, E., 
Diirr, H. and Jung, G. (1993) Bioorg. Med. Chem. Lett. 3, 937 
942. 
[31] Daniels, A.J., Matthews, J.E., Slepetits, R.T., Jansen, M., Vi- 
veros, O.H., Tadepalli, A., Harrington, W., Heyer, D., Landava- 
zo, A., Leban, J.J. and Spaltenstein, A. (1995) Proc. Natl. Acad. 
Sci. USA 92, 9067-9071. 
[32] Koradi, R., Billeter, M. and Wfithrich, K. (1996) J. Mol. 
Graphics 14, 51 55. 
